CD8A and melanoma: Thus, we investigated the administration of H89 on ex vivo cocultured CD8+ TLs, purified from OT-I mice, with melanoma B16-OVA for 48 h significantly decreased melanoma B16-OVA cell viability in 1:5 and 1:10 ratios (target:effector) (Figure 3I).